Efficacy of Noninvasive Ventilation in Amyotrophic Lateral Sclerosis (ALS)

Completed

• Conditions: Motor Neuron Disease; Amyotrophic Lateral Sclerosis

• Registration Number: NCT00537641
• Lead Sponsor: Columbia University

Brief Summary

This study will test the hypothesis that noninvasive ventilation (NIV) as prescribed in current medical practice for use in amyotrophic Lateral Sclerosis (ALS) patients fails to deliver adequate breathing support over a night of use in the patient's home. ALS patients who come to the ALS Center for their routine 3 month follow up exam and are currently using NIV will be asked to complete questionnaires regarding their quality of sleep, quality of life and general level of function, and to undergo a home sleep study, using a safe, comfortable and reliable breathing monitoring system during a night of sleep. If the questionnaires or the sleep study show failure of the breathing device, the investigators will work with the patient to fix the problem and then offer a second study to make sure that the changes were helpful. The results of this study may help to develop subsequent studies and to improve the guidelines used for care of ALS patients.

Detailed Description

Amyotrophic Lateral Sclerosis (ALS), also known as "Lou Gehrig's Disease", is a fatal disorder that causes breathing failure due to progressive weakness of the muscles of breathing. Breathing assist devices known as noninvasive ventilation (NIV) are offered to ALS patients when their breathing function worsens. These devices deliver breathing assistance via a mask on the nose or nose and mouth, and are thought to be particularly important to be used during sleep, when breathing often becomes more shallow and irregular. However, although these devices have become the standard of therapy in ALS patients once their lung function worsens, it remains unclear how effective these devices actually are when a patient is sleeping, partly because of the practical difficulties in applying the device properly and keeping it applied throughout the sleep period, and partly because they are most commonly prescribed without objective evidence regarding how much breathing support the patient needs as the disease progresses and the breathing muscles weaken further.

Study Timeline

• Study Start: 2007-05
• Study First Submitted: 2007-09-27
• Study First Submitted QC: 2007-09-27
• Study First Posted: 2007-10-01
• Primary Completion: 2010-07
• Study Completion: 2011-06
• Status Verified: 2015-07
• Last Update Submitted: 2015-07-02
• Last Update Posted: 2015-07-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

• clinical diagnosis of amyotrophic lateral sclerosis (El Escorial criteria)
• age 18 to 18 years old
• using nocturnal noninvasive ventilation to treat respiratory insufficiency at least 4 hours per night, for at least 4 nights per week

Exclusion Criteria

• inability to safely use NIPPV because of bulbar dysfunction
• indications for tracheostomy assisted ventilation due to inability to clear secretions from the airway
• presence of comorbid conditions with a life expectancy < 6 months
• presence of advanced dementia
• unwillingness to follow up at the Eleanor and Lou Gehrig ALS/MDA Center at Columbia University on a regular basis
• previously diagnosed obstructive sleep apnea
• residence outside the New York metropolitan area.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Tolerance of bilevel PAP	Up to 3 months	The ALS Functional Rating Scale - Revised (ALSFRS-R) will be administered to measure tolerance.
Score on Epworth Sleepiness Scale	Up to 3 months	Objective evidence of nocturnal sleep-disordered breathing on the bilevel PAP will be measured.

Trial Locations

Locations (1)

Eleanor and Lou Gehrig ALS/MDA Center at Columbia University; 🇺🇸 New York, New York, United States